

4/9/2004

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	TBA
Filing Date	
First Named Inventor	David Sidransky
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	001107.00463

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAC/		WEBER <i>et al.</i> , "Active Ras Induces Heterodimerization of cRaf and BRaf", <i>Cancer Research</i> , May 1, 2001, pp. 3595-3598, Vol. 61.	
		HOGREFE R., "An Antisense Oligonucleotide Primer", <i>Antisense and Nucleic Acid Drug Development</i> , 1999, Table 1 updated 2002, pp. 351-357, Vol. 9.	
		WILHELM <i>et al.</i> , "BAY 43-9006: Preclinical Data", <i>Current Pharmaceutical Design</i> , 2002, pp. 2255-2257, Vol. 8.	
		COHEN <i>et al.</i> , "BRAF Mutation in Papillary Thyroid Carcinoma", <i>Journal of the National Cancer Institute</i> , April 16, 2003, pp. 625-627, Vol. 95, No. 8.	
		NAMBA <i>et al.</i> , "Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers", <i>The Journal of Clinical Endocrinology & Metabolism</i> , 2003, pp. 4393-4397, Vol. 88(9).	
		HUANG <i>et al.</i> , "Gene Expression in Papillary Thyroid Carcinoma Reveals Highly Consistent Profiles", <i>Proceedings of the National Academy of Sciences</i> , December 18, 2001, pp. 15044-15049, Vol. 98, No. 26.	
		KIMURA <i>et al.</i> , "High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma", <i>Cancer Research</i> , April 1, 2003, pp. 1454-1457, Vol. 63.	
		DAUM <i>et al.</i> , "The Ins and Outs of Raf Kinases", <i>Elsevier Science Ltd.</i> , November 1994, pp. 474-480.	
		DAVIES <i>et al.</i> , "Mutations of the BRAF Gene in Human Cancer", <i>Nature</i> , June 27, 2002, pp. 949-954, Vol. 417.	
		CRIPPS <i>et al.</i> , "Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study", <i>Clinical Cancer Research</i> , July 2002, pp. 2188-2192, Vol. 8.	
		YIN <i>et al.</i> , "RNA-mediated Gene Regulation System: Now and the Future (Review)", <i>International Journal of Molecular Medicine</i> , 2002, pp. 355-365, Vol. 10.	
		COLLISSON <i>et al.</i> , "Treatment of Metastatic Melanoma with an Orally Available Inhibitor of the Ras-Raf-MAPK Cascade ^{1,2} ", <i>Cancer Research</i> , September 15, 2003, pp. 5669-5673, Vol. 63.	
		KOLCH <i>et al.</i> , "Animation of the Organisation and Function of the Ras-Raf-MEK-ERK Pathway", <i>Expert Reviews in Molecular Medicine</i> : http://www.expertreviews.org , Accession Information: (02)00444-1h.htm (shortcode: swf001 wkg); 14 August 2002 (Abstract only)	
✓		MULLEN <i>et al.</i> , "Antisense Oligonucleotide Targeting of raf-1: Importance of Raf-1 mRNA Expression Levels and Raf-1-Dependent Signaling in Determining Growth Response in Ovarian Cancer", <i>Clinical Cancer Research</i> , March 15, 2004, pp. 2100-8, Vol. 10(6). (Abstract only)	

Examiner
Signature

/Karen A. Canella, Ph.D./

Date
Considered

10/28/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	TBA
Filing Date	
First Named Inventor	David Sidransky
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	001107.00463

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

/Karen A. Canella, Ph.D./

Date
Considered

10/28/2007

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.